ClinicalTrials.Veeva

Menu

Evaluate the Efficacy and Safety of LMT1-48 on Reducing Body Fat in Overweight Subject

Medytox logo

Medytox

Status

Completed

Conditions

Overweight

Treatments

Dietary Supplement: Placebo
Dietary Supplement: LMT1-48

Study type

Interventional

Funder types

Industry

Identifiers

NCT03759743
MT13-KR17OWT712

Details and patient eligibility

About

The purpose of this study is to evaluate the safety and efficacy of LMT1-48(Probiotics) compared to a placebo in reducing the body fat in overweight subjects

Enrollment

97 patients

Sex

All

Ages

19 to 70 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Age between 19 and 70 years
  • Overweight (25 kg/m2 ≤ body mass index (BMI) < 30 kg/m2)

Exclusion criteria

  • Pregnancy or breast-feeding
  • Unstable body weight (body weight change > 10% within 3 months before screening)

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Quadruple Blind

97 participants in 2 patient groups, including a placebo group

Probiotics
Experimental group
Treatment:
Dietary Supplement: LMT1-48
Placebo
Placebo Comparator group
Treatment:
Dietary Supplement: Placebo

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems